Angiogenic biomarkers in pregnancy: defining maternal and fetal health

Research output: Contribution to journalReviewResearchpeer-review

Standard

Angiogenic biomarkers in pregnancy : defining maternal and fetal health. / Rasmussen, Lene G; Lykke, Jacob A; Staff, Anne C.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 94, No. 8, 08.2015, p. 820-32.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Rasmussen, LG, Lykke, JA & Staff, AC 2015, 'Angiogenic biomarkers in pregnancy: defining maternal and fetal health', Acta Obstetricia et Gynecologica Scandinavica, vol. 94, no. 8, pp. 820-32. https://doi.org/10.1111/aogs.12629

APA

Rasmussen, L. G., Lykke, J. A., & Staff, A. C. (2015). Angiogenic biomarkers in pregnancy: defining maternal and fetal health. Acta Obstetricia et Gynecologica Scandinavica, 94(8), 820-32. https://doi.org/10.1111/aogs.12629

Vancouver

Rasmussen LG, Lykke JA, Staff AC. Angiogenic biomarkers in pregnancy: defining maternal and fetal health. Acta Obstetricia et Gynecologica Scandinavica. 2015 Aug;94(8):820-32. https://doi.org/10.1111/aogs.12629

Author

Rasmussen, Lene G ; Lykke, Jacob A ; Staff, Anne C. / Angiogenic biomarkers in pregnancy : defining maternal and fetal health. In: Acta Obstetricia et Gynecologica Scandinavica. 2015 ; Vol. 94, No. 8. pp. 820-32.

Bibtex

@article{0e822acf23f347d09119d8669dea2d74,
title = "Angiogenic biomarkers in pregnancy: defining maternal and fetal health",
abstract = "We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes, and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have, in elderly patients, been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Hence dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs to possibly prevent, delay or reduce cardiovascular disease.",
keywords = "Antigens, CD, Biomarkers, Female, Fetal Growth Retardation, Humans, Pre-Eclampsia, Predictive Value of Tests, Pregnancy, Pregnancy Proteins, Receptors, Cell Surface, Vascular Endothelial Growth Factor Receptor-1",
author = "Rasmussen, {Lene G} and Lykke, {Jacob A} and Staff, {Anne C}",
note = "{\textcopyright} 2015 Nordic Federation of Societies of Obstetrics and Gynecology.",
year = "2015",
month = aug,
doi = "10.1111/aogs.12629",
language = "English",
volume = "94",
pages = "820--32",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "JohnWiley & Sons Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Angiogenic biomarkers in pregnancy

T2 - defining maternal and fetal health

AU - Rasmussen, Lene G

AU - Lykke, Jacob A

AU - Staff, Anne C

N1 - © 2015 Nordic Federation of Societies of Obstetrics and Gynecology.

PY - 2015/8

Y1 - 2015/8

N2 - We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes, and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have, in elderly patients, been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Hence dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs to possibly prevent, delay or reduce cardiovascular disease.

AB - We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes, and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have, in elderly patients, been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Hence dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs to possibly prevent, delay or reduce cardiovascular disease.

KW - Antigens, CD

KW - Biomarkers

KW - Female

KW - Fetal Growth Retardation

KW - Humans

KW - Pre-Eclampsia

KW - Predictive Value of Tests

KW - Pregnancy

KW - Pregnancy Proteins

KW - Receptors, Cell Surface

KW - Vascular Endothelial Growth Factor Receptor-1

U2 - 10.1111/aogs.12629

DO - 10.1111/aogs.12629

M3 - Review

C2 - 25753566

VL - 94

SP - 820

EP - 832

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 8

ER -

ID: 162372700